Azelastine, a phthalazinone derivative is classified as a potent long-acting anti-allergic compound with selective H1 antagonist properties. An additional anti-inflammatory effect could be detected after topical ocular administration. Data from in vivo (pre-clinical) and in vitro studies show that azelastine inhibits the synthesis or release of the chemical mediators known to be involved in early and late stage allergic reactions e.g. leukotriene, histamine, PAF and serotonin.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
Azelastine is the active ingredient of these drugs:
Cyprus Spain
Austria France Lithuania Netherlands Poland
Austria
Austria
Poland
Austria Ireland United States
Tunisia
Austria
Austria
Poland
Hong Kong Singapore
Hong Kong
Brazil
Ireland United Kingdom
Netherlands
Ireland United Kingdom
Brazil
Spain
Austria
Azelastine is also found within below combination drugs:
AZECORT , BILENI , DYMISTA , SYNAZE
Medicine agencies around the world have authorized marketing of this active ingredient according to these medication package inserts (MPIs):